This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Vifor Pharma's proposals to end probe provisionally accepted, UK's CMA says

( December 10, 2024, 07:43 GMT | Official Statement) -- MLex Summary: Vifor Pharma has made commitments to end a probe into whether it breached competition law in the market for iron treatments by disparaging a rival product, the UK antitrust regulator said. The company’s proposal includes a payment of 23 million pounds to the National Health Service and a communication campaign, the Competition and Markets Authority said. The regulator provisionally accepts the proposals, subject to views from interested parties.The statement follows:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections